REGN
Regeneron Pharmaceuticals IncPharmaceutical Preparations
$784.85updated Sep 19, 2026
Congressional trading profile for Regeneron Pharmaceuticals Inc (REGN), covering 14 disclosed transactions by 9 lawmakers.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Total Trades
14
Politicians Trading
9
Last Traded
Jul 7, 2026
Price history
Congressional Trades
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Alan ArmstrongR | Jul 21, 2026 | Mar 27, 2026 | Buy | $1,001 - $15,000 | +6.39% |
| Julia LetlowR | Mar 12, 2026 | Feb 12, 2026 | Buy | $1,001 - $15,000 | +0.15% |
| Robert BresnahanR | Jun 9, 2025 | May 15, 2025 | Buy | $1,001 - $15,000 | +34.16% |
| Byron DonaldsR | May 24, 2025 | Apr 10, 2025 | Sell | $1,001 - $15,000 | +43.64% |
| Byron DonaldsR | May 24, 2025 | Apr 10, 2025 | Sell | $1,001 - $15,000 | +43.64% |
| Robert BresnahanR | May 8, 2025 | Apr 8, 2025 | Sell | $1,001 - $15,000 | +40.95% |
| Jefferson ShreveR | May 8, 2025 | Apr 7, 2025 | Sell | $15,001 - $50,000 | +37.02% |
| Robert BresnahanR | Mar 27, 2025 | Feb 25, 2025 | Sell | $1,001 - $15,000 | +8.48% |